EUVIMEDEUVIMED entdecken
Open Access

Mechanism of Shuangshen Xionglian Granule in Attenuating EndMT in Atherosclerosis via the FGFR1–TGF‐β/Smad2 Axis

Xiaoshan Cui iD, Hailang Luo, Ran Zhang, Yuanyuan Chen, Hongzheng Li iD, Jiaming Gao, Huiyu Zhang, Wei Hao, Zikai Yu iD, Jianhua Fu iD, Hao Guo

Molecular Nutrition & Food Research · 2026

DOI: 10.1002/mnfr.70597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2026. Verfasst von Xiaoshan Cui und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Repu…. Hauptthemen laut MEDLINE: Smad2 Protein, Endothelial-Mesenchymal Transition, Atherosclerosis, Receptor, Fibroblast Growth Factor, Type 1. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: China Academy of Chinese Medical Sciences and Technology Innovation Project, National Natural Science Foundation of China, Xiyuan Hospital CACMS Enhancement Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shuangshen Xionglian Granule (SSXL), a multi‐herb traditional Chinese medicine used for atherosclerosis (AS), was investigated for its anti‐atherosclerotic effects and its role in modulating endothelial‐to‐mesenchymal transition (EndMT). In high‐fat diet–fed ApoE −/− mice, SSXL ameliorated dyslipidemia, reduced systemic inflammation, and alleviated aortic plaque burden. An integrated approach combining UPLC–QTOF–MS profiling, network pharmacology, and transcriptomics identified 401 SSXL‐responsive disease‐associated genes, which were enriched in pathways related to TGF‐β, MAPK, cAMP, and extracellular matrix organization. In both aortic tissues from these mice and TGF‐β2–stimulated human aortic endothelial cells, SSXL preserved endothelial identity and suppressed EndMT. Mechanistically, SSXL restored FGFR1 phosphorylation while concomitantly downregulating TGF‐βRI/TGF‐β2 expression and Smad2 phosphorylation. Pharmacological inhibition of FGFR1 with PD173074 partially abrogated these protective effects, indicating that SSXL suppresses EndMT, at least in part, through FGFR1‐mediated inhibition of the TGF‐β/Smad2 signaling axis. These findings suggest that SSXL ameliorates AS through combined lipid‐lowering, anti‐inflammatory, and anti‐EndMT actions, supporting its potential as a multi‐target therapeutic candidate for vascular protection in AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad2 ProteinEndothelial-Mesenchymal TransitionAtherosclerosisReceptor, Fibroblast Growth Factor, Type 1Drugs, Chinese HerbalTransforming Growth Factor betaAnimalsHumansMiceMaleSignal TransductionMice, Inbred C57BLDiet, High-FatEndothelial Cells

Stichwörter der Autor:innen

Shuangshen Xionglian GranuleTGF‐β/Smad signaling pathwayatherosclerosisendothelial‐to‐mesenchymal transitionfibroblast growth factor receptor 1

Substanzen

Smad2 ProteinReceptor, Fibroblast Growth Factor, Type 1Drugs, Chinese HerbalTransforming Growth Factor betaSmad2 protein, mouseFgfr1 protein, mouseShuangshen

Autor:innen und Institutionen

  • National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
  • China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
  • Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
  • Safety Evaluation Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Xiaoshan Cui, Hongzheng Li, Zikai Yu, Jianhua Fu

Förderung

  • China Academy of Chinese Medical Sciences and Technology Innovation Project
  • National Natural Science Foundation of China
  • Xiyuan Hospital CACMS Enhancement Fund
  • Graduate Science and Technology Innovation Project of China Academy of Chinese Medical Sciences
  • Fundamental Research Funds for the Central Public Welfare Research Institutes
  • Beijing Traditional Chinese Medicine Science and Technology Development Fund Project

Zitieren

APA

Cui, X., Luo, H., Zhang, R., Chen, Y., Li, H., Gao, J., Zhang, H., Hao, W., Yu, Z., Fu, J., & Guo, H. (2026). Mechanism of Shuangshen Xionglian Granule in Attenuating EndMT in Atherosclerosis via the FGFR1–TGF‐β/Smad2 Axis. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70597

Vancouver

Cui X, Luo H, Zhang R, Chen Y, Li H, Gao J, et al. Mechanism of Shuangshen Xionglian Granule in Attenuating EndMT in Atherosclerosis via the FGFR1–TGF‐β/Smad2 Axis. Molecular Nutrition & Food Research. 2026. doi:10.1002/mnfr.70597

BibTeX
@article{Cui2026,
  author = {Cui, Xiaoshan and Luo, Hailang and Zhang, Ran and Chen, Yuanyuan and Li, Hongzheng and Gao, Jiaming and Zhang, Huiyu and Hao, Wei and Yu, Zikai and Fu, Jianhua and Guo, Hao},
  title = {Mechanism of Shuangshen Xionglian Granule in Attenuating EndMT in Atherosclerosis via the FGFR1–TGF‐β/Smad2 Axis},
  journal = {Molecular Nutrition & Food Research},
  year = {2026},
  doi = {10.1002/mnfr.70597}
}
Kostenlos starten →